{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:16:36Z","timestamp":1794647796274,"version":"4.9.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"State Key Laboratory of National Security Specially Needed Medicines Program","award":["LTMC2022ZZ006"],"award-info":[{"award-number":["LTMC2022ZZ006"]}]},{"name":"State Key Laboratory of National Security Specially Needed Medicines Program","award":["LTMC2022ZZ006"],"award-info":[{"award-number":["LTMC2022ZZ006"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["32371504"],"award-info":[{"award-number":["32371504"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["32371504"],"award-info":[{"award-number":["32371504"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-024-01592-z","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T01:01:58Z","timestamp":1725238918000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation"],"prefix":"10.1186","volume":"17","author":[{"given":"Pengyun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiya","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijie","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengli","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changkai","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqiu","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhai","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"key":"1592_CR1","doi-asserted-by":"crossref","unstructured":"Fuchs O. Targeting cereblon in hematologic malignancies. Blood Rev. 2023;57.","DOI":"10.1016\/j.blre.2022.100994"},{"issue":"11","key":"1592_CR2","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1200\/JCO.23.01277","volume":"42","author":"F Maura","year":"2024","unstructured":"Maura F, Rajanna AR, Ziccheddu B, Poos AM, Derkach A, Maclachlan K, et al. Genomic classification and individualized prognosis in multiple myeloma. J Clin Oncol. 2024;42(11):1229\u201340.","journal-title":"J Clin Oncol"},{"issue":"10272","key":"1592_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410\u201327.","journal-title":"Lancet"},{"issue":"15","key":"1592_CR4","doi-asserted-by":"publisher","first-page":"6234","DOI":"10.1039\/D2CS00116K","volume":"51","author":"J Yamamoto","year":"2022","unstructured":"Yamamoto J, Ito T, Yamaguchi Y, Handa H. Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders. Chem Soc Rev. 2022;51(15):6234\u201350.","journal-title":"Chem Soc Rev"},{"issue":"6168","key":"1592_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343(6168):305\u20139.","journal-title":"Science"},{"issue":"10","key":"1592_CR6","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.1038\/bcj.2015.66","volume":"5","author":"CC Bjorklund","year":"2015","unstructured":"Bjorklund CC, Lu L, Kang J, Hagner PR, Havens CG, Amatangelo M, et al. Rate of CRL4(CRBN) substrate ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Blood Cancer J. 2015;5(10):e354.","journal-title":"Blood Cancer J"},{"issue":"7559","key":"1592_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nature14610","volume":"523","author":"J Kronke","year":"2015","unstructured":"Kronke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, et al. Lenalidomide induces ubiquitination and degradation of CK1alpha in Del(5q) MDS. Nature. 2015;523(7559):183\u20138.","journal-title":"Nature"},{"key":"1592_CR8","doi-asserted-by":"crossref","unstructured":"An J, Ponthier CM, Sack R, Seebacher J, Stadler MB, Donovan KA et al. pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase. Nat Commun. 2017;8(1).","DOI":"10.1038\/ncomms15398"},{"issue":"7611","key":"1592_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature18611","volume":"535","author":"ME Matyskiela","year":"2016","unstructured":"Matyskiela ME, Lu G, Ito T, Pagarigan B, Lu CC, Miller K, et al. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase. Nature. 2016;535(7611):252\u20137.","journal-title":"Nature"},{"key":"1592_CR10","doi-asserted-by":"publisher","first-page":"e38430","DOI":"10.7554\/eLife.38430","volume":"7","author":"KA Donovan","year":"2018","unstructured":"Donovan KA, An J, Nowak RP, Yuan JC, Fink EC, Berry BC, et al. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. eLife. 2018;7:e38430.","journal-title":"eLife"},{"issue":"10","key":"1592_CR11","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/s41589-018-0129-x","volume":"14","author":"ME Matyskiela","year":"2018","unstructured":"Matyskiela ME, Couto S, Zheng X, Lu G, Hui J, Stamp K, et al. SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate. Nat Chem Biol. 2018;14(10):981\u20137.","journal-title":"Nat Chem Biol"},{"key":"1592_CR12","doi-asserted-by":"crossref","unstructured":"Sievers QL, Petzold G, Bunker RD, Renneville A, Slabicki M, Liddicoat BJ et al. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science. 2018;362(6414).","DOI":"10.1126\/science.aat0572"},{"issue":"11","key":"1592_CR13","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1038\/s41589-019-0366-7","volume":"15","author":"T Asatsuma-Okumura","year":"2019","unstructured":"Asatsuma-Okumura T, Ando H, De Simone M, Yamamoto J, Sato T, Shimizu N, et al. p63 is a cereblon substrate involved in thalidomide teratogenicity. Nat Chem Biol. 2019;15(11):1077\u201384.","journal-title":"Nat Chem Biol"},{"issue":"3","key":"1592_CR14","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1158\/2643-3230.BCD-20-0105","volume":"2","author":"A Renneville","year":"2021","unstructured":"Renneville A, Gasser JA, Grinshpun DE, Jean Beltran PM, Udeshi ND, Matyskiela ME, et al. Avadomide induces degradation of ZMYM2 Fusion oncoproteins in Hematologic malignancies. Blood Cancer Discov. 2021;2(3):250\u201365.","journal-title":"Blood Cancer Discov"},{"key":"1592_CR15","doi-asserted-by":"crossref","unstructured":"Carter JL, Hege K, Yang J, Kalpage HA, Su Y, Edwards H et al. Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduct Tar. 2020;5(1).","DOI":"10.1038\/s41392-020-00361-x"},{"issue":"5","key":"1592_CR16","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464\u201377.","journal-title":"JAMA"},{"key":"1592_CR17","doi-asserted-by":"crossref","unstructured":"Jiang S, Zhang M, Sun J, Yang X. Casein kinase 1\u03b1: biological mechanisms and theranostic potential. Cell Commun Signal. 2018;16(1).","DOI":"10.1186\/s12964-018-0236-z"},{"key":"1592_CR18","doi-asserted-by":"publisher","first-page":"32384","DOI":"10.1074\/jbc.M109.052647","volume":"284","author":"A-S Huart","year":"2009","unstructured":"Huart A-S, MacLaine N, Meek D, Hupp T. CK1 alpha plays a Central Role in Mediating MDM2 Control of p53 and E2F-1 protein Stability. J Biol Chem. 2009;284:32384\u201394.","journal-title":"J Biol Chem"},{"issue":"11","key":"1592_CR19","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1182\/blood-2017-05-786947","volume":"131","author":"P Janovska","year":"2018","unstructured":"Janovska P, Verner J, Kohoutek J, Bryjova L, Gregorova M, Dzimkova M, et al. Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia. Blood. 2018;131(11):1206\u201318.","journal-title":"Blood"},{"key":"1592_CR20","doi-asserted-by":"crossref","unstructured":"Manni S, Carrino M, Piazza F. Role of protein kinases CK1\u03b1 and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways. J Hematol Oncol. 2017;10(1).","DOI":"10.1186\/s13045-017-0529-5"},{"issue":"4","key":"1592_CR21","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.ccell.2023.02.010","volume":"41","author":"S-M Park","year":"2023","unstructured":"Park S-M, Miyamoto DK, Han GYQ, Chan M, Curnutt NM, Tran NL, et al. Dual IKZF2 and CK1\u03b1 degrader targets acute myeloid leukemia cells. Cancer Cell. 2023;41(4):726\u2013e3911.","journal-title":"Cancer Cell"},{"key":"1592_CR22","doi-asserted-by":"crossref","unstructured":"Nishiguchi G, Mascibroda LG, Young SM, Caine EA, Abdelhamed S, Kooijman JJ et al. Selective CK1\u03b1 degraders exert antiproliferative activity against a broad range of human cancer cell lines. Nat Commun. 2024;15(1).","DOI":"10.1038\/s41467-024-44698-1"},{"key":"1592_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40364-020-0182-y","volume":"8","author":"S Gao","year":"2020","unstructured":"Gao S, Wang S, Song Y. Novel immunomodulatory drugs and neo-substrates. Biomark Res. 2020;8:2.","journal-title":"Biomark Res"},{"issue":"1","key":"1592_CR24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41467-021-27818-z","volume":"13","author":"S Yamanaka","year":"2022","unstructured":"Yamanaka S, Horiuchi Y, Matsuoka S, Kido K, Nishino K, Maeno M, et al. A proximity biotinylation-based approach to identify protein-E3 ligase interactions induced by PROTACs and molecular glues. Nat Commun. 2022;13(1):183.","journal-title":"Nat Commun"},{"key":"1592_CR25","doi-asserted-by":"publisher","first-page":"835299","DOI":"10.3389\/fonc.2022.835299","volume":"12","author":"Q Ran","year":"2022","unstructured":"Ran Q, Xu D, Wang Q, Wang D. Hypermethylation of the promoter region of miR-23 enhances the metastasis and proliferation of multiple myeloma cells via the aberrant expression of uPA. Front Oncol. 2022;12:835299.","journal-title":"Front Oncol"},{"issue":"9","key":"1592_CR26","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nsmb.2874","volume":"21","author":"PP Chamberlain","year":"2014","unstructured":"Chamberlain PP, Lopez-Girona A, Miller K, Carmel G, Pagarigan B, Chie-Leon B, et al. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol. 2014;21(9):803\u20139.","journal-title":"Nat Struct Mol Biol"},{"issue":"3","key":"1592_CR27","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","volume":"27","author":"GM Sastry","year":"2013","unstructured":"Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des. 2013;27(3):221\u201334.","journal-title":"J Comput Aided Mol Des"},{"issue":"12","key":"1592_CR28","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s10822-007-9133-z","volume":"21","author":"JC Shelley","year":"2007","unstructured":"Shelley JC, Cholleti A, Frye LL, Greenwood JR, Timlin MR, Uchimaya M. Epik: a software program for pK(a) prediction and protonation state generation for drug-like molecules. J Comput Aided Mol Des. 2007;21(12):681\u201391.","journal-title":"J Comput Aided Mol Des"},{"issue":"21","key":"1592_CR29","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1021\/jm051256o","volume":"49","author":"RA Friesner","year":"2006","unstructured":"Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem. 2006;49(21):6177\u201396.","journal-title":"J Med Chem"},{"issue":"16","key":"1592_CR30","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jcc.20291","volume":"26","author":"D Van Der Spoel","year":"2005","unstructured":"Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ. GROMACS: fast, flexible, and free. J Comput Chem. 2005;26(16):1701\u201318.","journal-title":"J Comput Chem"},{"issue":"9","key":"1592_CR31","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/jcc.20035","volume":"25","author":"J Wang","year":"2004","unstructured":"Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general amber force field. J Comput Chem. 2004;25(9):1157\u201374.","journal-title":"J Comput Chem"},{"issue":"16","key":"1592_CR32","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/jcc.20290","volume":"26","author":"DA Case","year":"2005","unstructured":"Case DA, Cheatham TE 3rd, Darden T, Gohlke H, Luo R, Merz KM Jr., et al. The Amber biomolecular simulation programs. J Comput Chem. 2005;26(16):1668\u201388.","journal-title":"J Comput Chem"},{"key":"1592_CR33","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/1756-0500-5-367","volume":"5","author":"AW Sousa da Silva","year":"2012","unstructured":"Sousa da Silva AW, Vranken WF. ACPYPE - AnteChamber PYthon Parser interfacE. BMC Res Notes. 2012;5:367.","journal-title":"BMC Res Notes"},{"issue":"8","key":"1592_CR34","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","volume":"11","author":"JA Maier","year":"2015","unstructured":"Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C. ff14SB: improving the Accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput. 2015;11(8):3696\u2013713.","journal-title":"J Chem Theory Comput"},{"issue":"10","key":"1592_CR35","doi-asserted-by":"publisher","first-page":"104107","DOI":"10.1063\/1.2711202","volume":"126","author":"M Springborg","year":"2007","unstructured":"Springborg M, Kirtman B. Efficient vector potential method for calculating electronic and nuclear response of infinite periodic systems to finite electric fields. J Chem Phys. 2007;126(10):104107.","journal-title":"J Chem Phys"},{"issue":"D1","key":"1592_CR36","doi-asserted-by":"publisher","first-page":"D1211","DOI":"10.1093\/nar\/gky869","volume":"47","author":"J Ma","year":"2019","unstructured":"Ma J, Chen T, Wu S, Yang C, Bai M, Shu K, et al. iProX: an integrated proteome resource. Nucleic Acids Res. 2019;47(D1):D1211\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"1592_CR37","doi-asserted-by":"publisher","first-page":"D1522","DOI":"10.1093\/nar\/gkab1081","volume":"50","author":"T Chen","year":"2022","unstructured":"Chen T, Ma J, Liu Y, Chen Z, Xiao N, Lu Y, et al. iProX in 2021: connecting proteomics data sharing with big data. Nucleic Acids Res. 2022;50(D1):D1522\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"1592_CR38","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1182\/blood-2018-01-828418","volume":"132","author":"A Patil","year":"2018","unstructured":"Patil A, Manzano M, Gottwein E. CK1\u03b1 and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma. Blood. 2018;132(6):577\u201386.","journal-title":"Blood"},{"issue":"1","key":"1592_CR39","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.cellsig.2012.09.008","volume":"25","author":"SA Rushworth","year":"2013","unstructured":"Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, MacEwan DJ. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-\u03baB. Cell Signal. 2013;25(1):106\u201312.","journal-title":"Cell Signal"},{"issue":"Supplement 1","key":"1592_CR40","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.1182\/blood-2023-186614","volume":"142","author":"Y Li","year":"2023","unstructured":"Li Y, Barber A, Martin S, Morales S, Bird S, Chrisochoidou Y, et al. EZH2 inhibition overcomes Immunomodulatory Drug (IMiD) Resistance in multiple myeloma cell lines in a Cereblon Pathway Dependent Manner. Blood. 2023;142(Supplement 1):4187.","journal-title":"Blood"},{"issue":"11","key":"1592_CR41","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41568-019-0196-7","volume":"19","author":"JH Bushweller","year":"2019","unstructured":"Bushweller JH. Targeting transcription factors in cancer \u2014 from undruggable to reality. Nat Rev Cancer. 2019;19(11):611\u201324.","journal-title":"Nat Rev Cancer"},{"key":"1592_CR42","doi-asserted-by":"crossref","unstructured":"Wang Z-Q, Zhang Z-C, Wu Y-Y, Pi Y-N, Lou S-H, Liu T-B et al. Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy. Signal Transduct Tar. 2023;8(1).","DOI":"10.1038\/s41392-023-01647-6"},{"key":"1592_CR43","doi-asserted-by":"publisher","first-page":"13191","DOI":"10.2147\/OTT.S286867","volume":"13","author":"X Zhu","year":"2020","unstructured":"Zhu X, Liao Y, Tang L. Targeting BRD9 for Cancer Treatment: a New Strategy. OncoTargets Ther. 2020;13:13191\u2013200.","journal-title":"OncoTargets Ther"},{"issue":"24","key":"1592_CR44","doi-asserted-by":"publisher","first-page":"16953","DOI":"10.1021\/acs.jmedchem.3c01736","volume":"66","author":"DK Miyamoto","year":"2023","unstructured":"Miyamoto DK, Curnutt NM, Park S-M, Stavropoulos A, Kharas MG, Woo CM. Design and development of IKZF2 and CK1\u03b1 dual degraders. J Med Chem. 2023;66(24):16953\u201379.","journal-title":"J Med Chem"},{"issue":"1","key":"1592_CR45","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41375-018-0205-y","volume":"33","author":"J Liu","year":"2019","unstructured":"Liu J, Song T, Zhou W, Xing L, Wang S, Ho M, et al. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity. Leukemia. 2019;33(1):171\u201380.","journal-title":"Leukemia"},{"issue":"4","key":"1592_CR46","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","volume":"34","author":"CC Bjorklund","year":"2019","unstructured":"Bjorklund CC, Kang J, Amatangelo M, Polonskaia A, Katz M, Chiu H, et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia. 2019;34(4):1197\u2013201.","journal-title":"Leukemia"},{"issue":"13","key":"1592_CR47","doi-asserted-by":"publisher","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","volume":"63","author":"JD Hansen","year":"2020","unstructured":"Hansen JD, Correa M, Nagy MA, Alexander M, Plantevin V, Grant V, et al. Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma. J Med Chem. 2020;63(13):6648\u201376.","journal-title":"J Med Chem"},{"key":"1592_CR48","doi-asserted-by":"publisher","first-page":"CT186","DOI":"10.1158\/1538-7445.AM2022-CT186","volume":"82","author":"S Lonial","year":"2022","unstructured":"Lonial S, Richard S, Matous J, Yee A, Shah U, Mehta-Shah N, et al. Pharmacokinetic (PK) profile of a novel IKZF1\/3 degrader, CFT7455, enables significant potency advantage over other IKZF1\/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1\/2 study of CFT7455 in MM. Cancer Res. 2022;82:CT186\u2013CT.","journal-title":"Cancer Res"},{"issue":"23","key":"1592_CR49","doi-asserted-by":"publisher","first-page":"eabg2697","DOI":"10.1126\/sciadv.abg2697","volume":"7","author":"J Liu","year":"2021","unstructured":"Liu J, Hideshima T, Xing L, Wang S, Zhou W, Samur MK, et al. ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment. Sci Adv. 2021;7(23):eabg2697.","journal-title":"Sci Adv"},{"key":"1592_CR50","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1182\/blood.V130.Suppl_1.63.63","volume":"130","author":"P Neri","year":"2017","unstructured":"Neri P, Tagoug I, Maity R, Stein CK, Kong M, Keats J, et al. Transcriptional plasticity compensates for Ikaros and Aiolos Proteasomal Degradation and mediates resistance to IMiDs in multiple myeloma (MM). Blood. 2017;130:63.","journal-title":"Blood"},{"key":"1592_CR51","doi-asserted-by":"crossref","unstructured":"Zhu YX, Shi C-X, Bruins LA, Wang X, Riggs DL, Porter B et al. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4. Blood Cancer J. 2019;9(2).","DOI":"10.1038\/s41408-019-0173-0"},{"issue":"2","key":"1592_CR52","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/1878-0261.12157","volume":"12","author":"K Dimopoulos","year":"2017","unstructured":"Dimopoulos K, S\u00f8gaard Helbo A, Fibiger Munch-Petersen H, Sj\u00f6 L, Christensen J, Sommer Kristensen L, et al. Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon\u2010independent manner. Mol Oncol. 2017;12(2):180\u201395.","journal-title":"Mol Oncol"},{"issue":"9","key":"1592_CR53","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1158\/1078-0432.CCR-22-3668","volume":"29","author":"K Kurata","year":"2023","unstructured":"Kurata K, Samur MK, Liow P, Wen K, Yamamoto L, Liu J, et al. BRD9 degradation disrupts Ribosome Biogenesis in multiple myeloma. Clin Cancer Res. 2023;29(9):1807\u201321.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1592_CR54","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.21037\/tcr-21-42","volume":"10","author":"L Zhou","year":"2021","unstructured":"Zhou L, Yao Q, Li H, Chen J. Targeting BRD9 by I-BRD9 efficiently inhibits growth of acute myeloid leukemia cells. Transl Cancer Res. 2021;10(7):3364\u201372.","journal-title":"Transl Cancer Res"},{"key":"1592_CR55","doi-asserted-by":"crossref","unstructured":"Weisberg E, Chowdhury B, Meng C, Case AE, Ni W, Garg S et al. BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma. Blood Cancer J. 2022;12(7).","DOI":"10.1038\/s41408-022-00704-7"},{"issue":"23","key":"1592_CR56","doi-asserted-by":"publisher","first-page":"4338","DOI":"10.1111\/bph.14493","volume":"175","author":"C Mi","year":"2018","unstructured":"Mi C, Wang Z, Li MY, Zhang ZH, Ma J, Jin X. Zinc finger protein 91 positively regulates the production of IL-1\u03b2 in macrophages by activation of MAPKs and non-canonical caspase-8 inflammasome. Brit J Pharmacol. 2018;175(23):4338\u201352.","journal-title":"Brit J Pharmacol"},{"issue":"13","key":"1592_CR57","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1182\/blood.2021014701","volume":"139","author":"W Wu","year":"2022","unstructured":"Wu W, Nelson GM, Koch R, Donovan KA, Nowak RP, Heavican-Foral TB, et al. Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1. Blood. 2022;139(13):2024\u201337.","journal-title":"Blood"},{"issue":"11","key":"1592_CR58","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/s41556-019-0416-0","volume":"21","author":"Y Wang","year":"2019","unstructured":"Wang Y, Yuan S, Jia X, Ge Y, Ling T, Nie M, et al. Mitochondria-localised ZNFX1 functions as a dsRNA sensor to initiate antiviral responses through MAVS. Nat Cell Biol. 2019;21(11):1346\u201356.","journal-title":"Nat Cell Biol"},{"key":"1592_CR59","doi-asserted-by":"crossref","unstructured":"He A, He S, Li X, Zhou L. ZFAS1: a novel vital oncogenic lncRNA in multiple human cancers. Cell Prolif. 2018;52(1).","DOI":"10.1111\/cpr.12513"},{"key":"1592_CR60","doi-asserted-by":"crossref","unstructured":"Wensheng L, Bo Z, Qiangsheng H, Wenyan X, Shunrong J, Jin X et al. MBD1 promotes the malignant behavior of gallbladder cancer cells and induces chemotherapeutic resistance to gemcitabine. Cancer Cell Int. 2019;19(1).","DOI":"10.1186\/s12935-019-0948-1"},{"key":"1592_CR61","doi-asserted-by":"crossref","unstructured":"Ding Y, Wang H, Liu J, Jiang H, Gong A, Xu M. MBD3 as a potential biomarker for Colon cancer: implications for epithelial-mesenchymal transition (EMT) pathways. Cancers. 2023;15(12).","DOI":"10.3390\/cancers15123185"},{"key":"1592_CR62","doi-asserted-by":"crossref","unstructured":"Wang H, Min J, Ding Y, Yu Z, Zhou Y, Wang S et al. MBD3 promotes epithelial-mesenchymal transition in gastric cancer cells by upregulating ACTG1 via the PI3K\/AKT pathway. Biol Proced Online. 2024;26(1).","DOI":"10.1186\/s12575-023-00228-9"},{"issue":"4","key":"1592_CR63","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/s41416-022-01831-5","volume":"127","author":"W Yan","year":"2022","unstructured":"Yan W, Han Q, Gong L, Zhan X, Li W, Guo Z, et al. MBD3 promotes hepatocellular carcinoma progression and metastasis through negative regulation of tumour suppressor TFPI2. Brit J Cancer. 2022;127(4):612\u201323.","journal-title":"Brit J Cancer"},{"issue":"13","key":"1592_CR64","first-page":"1019","volume":"135","author":"HV Nguyen","year":"2020","unstructured":"Nguyen HV, Vandenberg CJ, Ng AP, Robati MR, Anstee NS, Rimes J, et al. Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis. Blood. 2020;135(13):1019\u201331.","journal-title":"Blood"},{"issue":"4","key":"1592_CR65","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/s41418-023-01119-y","volume":"30","author":"HV Nguyen","year":"2023","unstructured":"Nguyen HV, Vandenberg CJ, Robati MR, Ng AP, Cory S. MNT suppresses T cell apoptosis via BIM and is critical for T lymphomagenesis. Cell Death Differ. 2023;30(4):1018\u201332.","journal-title":"Cell Death Differ"},{"issue":"7","key":"1592_CR66","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.4049\/jimmunol.0904028","volume":"184","author":"AM Thornton","year":"2010","unstructured":"Thornton AM, Korty PE, Tran DQ, Wohlfert EA, Murray PE, Belkaid Y, et al. Expression of Helios, an Ikaros Transcription Factor Family Member, differentiates thymic-derived from peripherally Induced Foxp3\u2009+\u2009T Regulatory cells. J Immunol. 2010;184(7):3433\u201341.","journal-title":"J Immunol"},{"issue":"22","key":"1592_CR67","doi-asserted-by":"publisher","first-page":"6248","DOI":"10.1073\/pnas.1604765113","volume":"113","author":"H Nakagawa","year":"2016","unstructured":"Nakagawa H, Sido JM, Reyes EE, Kiers V, Cantor H, Kim H-J. Instability of Helios-deficient Tregs is associated with conversion to a T-effector phenotype and enhanced antitumor immunity. P Natl Acad Sci USA. 2016;113(22):6248\u201353.","journal-title":"P Natl Acad Sci USA"},{"issue":"7597","key":"1592_CR68","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nature16979","volume":"532","author":"G Petzold","year":"2016","unstructured":"Petzold G, Fischer ES, Thom\u00e4 NH. Structural basis of lenalidomide-induced CK1\u03b1 degradation by the CRL4CRBN ubiquitin ligase. Nature. 2016;532(7597):127\u201330.","journal-title":"Nature"},{"issue":"14","key":"1592_CR69","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1182\/blood-2018-05-852798","volume":"132","author":"EC Fink","year":"2018","unstructured":"Fink EC, McConkey M, Adams DN, Haldar SD, Kennedy JA, Guirguis AA, et al. CrbnI391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. Blood. 2018;132(14):1535\u201344.","journal-title":"Blood"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01592-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-024-01592-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01592-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T02:05:37Z","timestamp":1725242737000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-024-01592-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1592"],"URL":"https:\/\/doi.org\/10.1186\/s13045-024-01592-z","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,2]]},"assertion":[{"value":"22 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal studies were performed strictly in accordance with the Animal Care Guidelines approved by the Institutional Animal Care Committee of Beijing Institute of Biotechnology. The human related materials were included MM cells and tumor tissues, and the use of human experimental materials, including cDNA derived from cell lines and clinical specimens, have been reviewed and approved by Ethics Committee of the General Hospital of Central Theater Command. All the experiments using the human related materials were performed according to the Helsinki Declaration (WHO).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}